Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCraven House Capital Regulatory News (CRV)

  • This share is currently suspended. It was suspended at a price of 0.125
  • There is currently no data for CRV

Issue of Equity

18 Mar 2015 13:00

RNS Number : 7908H
Craven House Capital PLC
18 March 2015
Β 

18 March 2015

Β 

Β 

Β Craven House Capital Plc ("Craven House" or "the Company")

Β 

Issue of Equity

Β 

The Company today announces that as disclosed in the announcement on 27 February 2015 of the Company's interim results for the period ended 30 November 2014, under the terms of the management services agreement (the "Management Services Agreement") entered into with Desmond Holdings Ltd ("Desmond"), the Company's Investment Manager, Desmond has been awarded a performance fee of Β£88,429 for the period ended 30 November 2014.

Β 

On 2 August 2011, the Company announced the terms of their Management Services Agreement with Desmond. Under this agreement, the Company agreed to pay Desmond, as Investment Manager, an annual performance fee equal to 20% of the increase in the Net Asset Value of the Company, subject to a hurdle rate of at least 5% (the "Performance Fee"). These conditions have been fulfilled, and the Company has calculated Desmond's Performance fee accordingly.

Β 

This Performance Fee will be paid by the issue of 7,074,315 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") to Desmond, at a price of 1.25 pence per Ordinary Share.

Application has been made to the London Stock Exchange for the 7,074,315 new Ordinary Shares to be admitted to trading on AIM. Admission is expected to take place on or about 23 March 2015. The shares will rank pari passu with the existing issued ordinary shares.

Β 

Following the issue of the new ordinary shares, the Company's total issued share capital will consist of 805,540,872 ordinary shares with each share carrying the right to one vote. The Company has no ordinary shares held in treasury. The total of 805,540,872 ordinary shares may therefore be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

Β 

~ Ends ~

Β 

Β 

Β 

For further information please contact:

Β 

Craven House Capital Plc

Alexandra Eavis

Non-Executive Director and Company Secretary

www.Cravenhousecapital.com

Β 

Tel: 07590 831 323

Β 

Β 

SPARK Advisory Partners Limited

Nominated Adviser

Matt Davis/Mark Brady

Β 

Tel: 0203 368 3550

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IOELVLFFEXFLBBQ
Date   Source Headline
24th Jul 20257:00 amRNSCancellation - Craven House Capital PLC
23rd Jun 202510:30 amRNSWithdrawl of 'Stmt re Share Price Movement' RNS
23rd Jun 202510:05 amRNSStatement re Share Price Movement
23rd Jun 20257:30 amRNSSuspension - Craven House Capital Plc
23rd Jun 20257:00 amRNSResignation of Nominated Adviser
27th Feb 20257:00 amRNSInterim Results
7th Feb 20254:22 pmRNSTR-1: Notification of major holdings
16th Dec 20242:42 pmRNSResult of AGM
15th Nov 20247:00 amRNSAnnual Results For Year Ended 31 May 2024
10th Sep 20247:00 amRNSInvestee company update: RoseMonkey Ltd
27th Aug 20247:00 amRNSTR-1: Notification of major holdings
23rd Aug 20242:19 pmRNSTR-1: notification of major holdings
5th Jun 20247:00 amRNSInvestee Companies' Update: Bio Vitos
28th Feb 20247:00 amRNSInterim Results
4th Jan 20247:00 amRNSResult of Annual General Meeting
29th Nov 20232:48 pmRNSAnnual Results for year ended 31 May 2023
28th Nov 20234:08 pmRNSInvestee Companies' Update
16th Nov 20239:07 amRNSInvestee Companies’ Update: Garimon and Honeydog
23rd Oct 20237:00 amRNSInvestee company update: Bio Vitos
17th Oct 20237:46 amRNSInvestee Companies’ Update: Garimon and Honeydog
29th Aug 20231:34 pmRNSInvestee company update: Bio Vitos
3rd Jul 20231:32 pmRNSInvestee company update: Bio Vitos
3rd Mar 20236:15 pmRNSPortfolio Update
27th Feb 20233:30 pmRNSInterim Results
8th Feb 20237:00 amRNSInvestee company update: Bio Vitos
27th Jan 202311:33 amRNSResult of Annual General Meeting
29th Nov 20227:00 amRNSAnnual Results for Year Ended 31 May 2022
15th Nov 20222:42 pmRNSInvestee company update: Garimon Ltd
23rd Feb 20223:01 pmRNSInterim Results
21st Jan 202212:45 pmRNSResult of AGM
23rd Dec 20213:59 pmRNSNotice of AGM
29th Nov 20216:29 pmRNSAnnual Results for year ended 31 May 2021
24th Nov 20212:55 pmRNSInvestee company update: OneBas.Com Ltd.
26th Oct 20217:00 amRNSInvestee company update: YRRO Ltd
16th Mar 20211:06 pmRNSTR-1: Notification of major holdings
18th Feb 20213:07 pmRNSInterim Results
11th Feb 202111:21 amRNSTR-1: Notification of major holdings
5th Feb 202110:44 amRNSStatement Regarding Share Price Movement
18th Jan 20212:49 pmRNSResult of Annual General Meeting
21st Dec 20207:00 amRNSNotice of General Meeting
9th Dec 20207:00 amRNSInvestee Company Update: YRRO Ltd
3rd Dec 202012:43 pmRNSAnnual Results for year ended 31 May 2020
9th Nov 20209:45 amRNSChange of Auditor
9th Oct 20203:14 pmRNSTrading Update, Change of Auditor & 2020 Results
18th Sep 202010:57 amRNSInvestee company update: Magazinos.com
22nd Jun 20201:01 pmRNSTR-1: Notification of major holdings
18th Jun 202011:06 amRNSSecond Price Monitoring Extn
18th Jun 202011:00 amRNSPrice Monitoring Extension
3rd Jun 20201:27 pmRNSTR-1: Notification of major holdings
1st Jun 20202:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.